Literature DB >> 2703406

Molecular enzymology of the reductive bioactivation of hypoxic cell cytotoxins.

M I Walton1, C R Wolf, P Workman.   

Abstract

The hypoxic cell cytotoxins SR 4233, benznidazole (Benzo), and CB 1954 were readily reduced by anaerobic mouse liver microsomes in vitro to their respective amino or single N-oxide derivatives. The reactions were inhibited in air and required reduced cofactors, particularly NADPH. The rates of reductive bioactivation were markedly different for each drug, with SR 4233 much greater than CB 1954 greater than Benzo. Using purified cytochrome P-450 reductase (P-450 reductase) and an inhibitory antibody to this enzyme, we demonstrated that P-450 reductase was involved in the reductive bioactivation of all 3 compounds. It had a minor role in SR 4233 reduction, but a more important involvement in CB 1954 metabolism to its 4-amino metabolite. Using carbon monoxide, a specific inhibitor of cytochrome P-450 (P-450), we demonstrated that P-450 was involved in both SR 4233 and Benzo reduction. P-450 had a major role both in SR 4233 conversion to SR 4317 and in the latter steps of Benzo amine formation. Purified xanthine oxidase was shown to reduce SR 4233 and Benzo in vitro, but cytosolic aldehyde oxidase activity was only detectable with Benzo as substrate. Characterizing the relative participation of the various reductases in tumor versus normal tissues may allow a more rational selection and application of hypoxic cell cytotoxins in cancer therapy.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2703406     DOI: 10.1016/0360-3016(89)90900-0

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  20 in total

1.  Computational models to assign biopharmaceutics drug disposition classification from molecular structure.

Authors:  Akash Khandelwal; Praveen M Bahadduri; Cheng Chang; James E Polli; Peter W Swaan; Sean Ekins
Journal:  Pharm Res       Date:  2007-09-11       Impact factor: 4.200

Review 2.  Molecular chemotherapy for breast cancer.

Authors:  A Patterson; A L Harris
Journal:  Drugs Aging       Date:  1999-02       Impact factor: 3.923

3.  Hypoxia-selective, enzymatic conversion of 6-nitroquinoline into a fluorescent helicene: pyrido[3,2-f]quinolino[6,5-c]cinnoline 3-oxide.

Authors:  Anuruddha Rajapakse; Kent S Gates
Journal:  J Org Chem       Date:  2012-03-19       Impact factor: 4.354

4.  Enzymatic conversion of 6-nitroquinoline to the fluorophore 6-aminoquinoline selectively under hypoxic conditions.

Authors:  Anuruddha Rajapakse; Collette Linder; Ryan D Morrison; Ujjal Sarkar; Nathan D Leigh; Charles L Barnes; J Scott Daniels; Kent S Gates
Journal:  Chem Res Toxicol       Date:  2013-04-02       Impact factor: 3.739

Review 5.  Assessing the bioreductive effectiveness of the nitroimidazole RSU1069 and its prodrug RB6145: with particular reference to in vivo methods of evaluation.

Authors:  J C Bremner
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

6.  Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069.

Authors:  A V Patterson; M P Saunders; E C Chinje; D C Talbot; A L Harris; I J Strafford
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

7.  SR 4233 cytotoxicity and metabolism in DNA repair-competent and repair-deficient cell cultures.

Authors:  K A Biedermann; J Wang; R P Graham; J M Brown
Journal:  Br J Cancer       Date:  1991-03       Impact factor: 7.640

8.  The effects of three bioreductive drugs (mitomycin C, RSU-1069 and SR4233) on cell lines selected for their sensitivity to mitomycin C or ionising radiation.

Authors:  A Keohane; J Godden; I J Stratford; G E Adams
Journal:  Br J Cancer       Date:  1990-05       Impact factor: 7.640

Review 9.  The experimental development of bioreductive drugs and their role in cancer therapy.

Authors:  P Workman; I J Stratford
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

10.  Metabolism of the bioreductive cytotoxin SR 4233 by tumour cells: enzymatic studies.

Authors:  J Wang; K A Biedermann; C R Wolf; J M Brown
Journal:  Br J Cancer       Date:  1993-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.